Published 2026-09-15 · Last reviewed 2026-09-16 · By Andy Palenzuela, Founder
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both precursors the body can use to make NAD+, a coenzyme central to cellular energy metabolism. They sit one step apart in the same pathway: NR is converted to NMN, and NMN is converted to NAD+.
Age Revive's CELLUNAD+ uses 500 mg of NR per daily serving — not NMN — because NR has published human pharmacokinetic and tolerability data (Trammell 2016; Martens 2018). Those studies evaluated NR as an ingredient; they did not test the finished CELLUNAD+ formula, and they do not establish disease prevention, treatment, or lifespan effects.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. It shuttles electrons in the reactions that turn food into usable energy and serves as a substrate for enzyme families involved in DNA maintenance and cellular signaling, including sirtuins and PARPs.
Cells constantly consume and rebuild NAD+. Most of the rebuilding happens through the salvage pathway, which recycles nicotinamide and related molecules back into NAD+. "NAD+ precursors" are dietary compounds that feed this pathway. Vitamin B3 forms (niacin and nicotinamide), NR, and NMN are all precursors; they enter the pathway at different points.
Nicotinamide riboside (NR) is a form of vitamin B3: a nicotinamide molecule attached to a ribose sugar. It occurs in trace amounts in milk and is sold as a dietary supplement ingredient.
Nicotinamide mononucleotide (NMN) is NR with a phosphate group added. Inside the cell it is the direct precursor to NAD+. It is also sold as a supplement ingredient, and its regulatory status as a dietary ingredient in the United States has changed more than once in recent years.
Structurally the two molecules differ by that one phosphate group. Functionally, that difference determines how each one is handled before it can be used.
Both molecules are used through the same enzymes. NR is phosphorylated by nicotinamide riboside kinases (NRK1 and NRK2) to form NMN. NMN is then joined to an adenine nucleotide by NMNAT enzymes to form NAD+. NR is therefore one step earlier in the pathway than NMN, and NR must pass through NMN on its way to NAD+.
The difference is in getting into the cell. NR is a small, uncharged nucleoside and can be taken up by nucleoside transporters. NMN carries a charged phosphate group. Research in cells and mice indicates that NMN supplied from outside the cell is largely dephosphorylated to NR at the cell surface, taken up as NR, and then re-phosphorylated by NRK1 — which the same work found to be required for cells to use either NR or NMN (Ratajczak 2016). A separate line of research has proposed a dedicated NMN transporter in some tissues; that question remains debated in the literature, and Age Revive takes no position on it.
Practically, this means the two precursors converge quickly on the same route. The distinctions that matter for a buyer are which molecule has human data at a stated dose, and whether that dose is what a product actually delivers.
NR and NMN are not the only forms of vitamin B3 that lead to NAD+. Two older, cheaper ones are on most multivitamin labels, and both are worth understanding before comparing the newer precursors.
Nicotinic acid (niacin) reaches NAD+ by its own route, called the Preiss-Handler pathway: niacin → nicotinic acid mononucleotide → nicotinic acid adenine dinucleotide (NAAD) → NAD+. It works, and it is inexpensive. Its well-known drawback is flushing — the skin reddening and warmth that occurs at higher doses, caused by niacin activating a receptor on skin cells. That is why niacin is rarely used as a longevity precursor: the doses that would matter are the doses that flush.
Nicotinamide (niacinamide) is the form of B3 released every time NAD+ is consumed by an enzyme. The body recycles it back to NAD+ through the salvage pathway: nicotinamide → NMN → NAD+. The first step depends on an enzyme called NAMPT, which is generally considered the bottleneck of that route. At high doses, surplus nicotinamide is cleared through a methyl-consuming step, and in laboratory studies it can feed back on some of the enzymes that use NAD+. Nicotinamide does not cause flushing.
Where NR and NMN differ from both: NR is converted to NMN by its own dedicated kinases (NRK1 and NRK2), then to NAD+ — a route that bypasses the NAMPT bottleneck and does not involve the flushing receptor. NMN sits one step later on that same route. That is the pathway logic behind choosing a newer precursor over a commodity one; it is not a claim that niacin or nicotinamide do not work.
| Form | Route to NAD+ | Flushing | Notes |
|---|---|---|---|
| Nicotinic acid (niacin) | Preiss-Handler | Yes, at higher doses | Inexpensive; dose-limited by flushing |
| Nicotinamide (niacinamide) | Salvage, via NAMPT | No | NAMPT-dependent; high doses cleared by a methyl-consuming step |
| Nicotinamide riboside (NR) | NRK1/2 → NMN → NAD+ | No | Bypasses NAMPT; published human PK data (Trammell 2016) |
| Nicotinamide mononucleotide (NMN) | → NAD+ (transport route debated) | No | One step after NR; lawful dietary ingredient |
A full explainer on NR's chemistry, the three human trials, and dosing is in What Is Nicotinamide Riboside?. The methylation demand created by nicotinamide clearance — and why CELLUNAD+ includes TMG, methylfolate, B12, and B6 — is covered in Should You Take TMG With NR?.
Trammell 2016 was a pharmacokinetic study. In humans, single oral doses of 100 mg, 300 mg, and 1,000 mg of NR were given to 12 healthy adults, alongside a single-subject time course and mouse experiments. The study reported that NR was orally bioavailable and raised blood NAD+ in a dose-dependent manner. It measured NAD+ metabolites, not health outcomes.
Martens 2018 was a randomized, placebo-controlled crossover trial in 24 healthy adults aged 55 to 79. Participants took 500 mg of NR twice daily — 1,000 mg per day — for six weeks, and placebo for six weeks. The study reported that NR was well tolerated and that NAD+ in peripheral blood mononuclear cells rose by roughly 60% during supplementation. Blood pressure and arterial-stiffness measures were exploratory, and the authors described them as hypothesis-generating.
Dose matters when reading these results against a product. CELLUNAD+ provides 500 mg of NR per daily serving — half the daily dose used in Martens 2018. Age Revive states this plainly rather than implying the product replicates the study.
The studies above measured NAD+ levels and tolerability in small groups of healthy adults over days to weeks. They did not measure disease outcomes, lifespan, or long-term safety, and they were not designed to.
Neither study tested CELLUNAD+ or any multi-ingredient formula. Results for an ingredient do not transfer automatically to a finished product with a different dose and additional components.
No head-to-head human trial cited here compares NR with NMN on health outcomes. Age Revive does not claim CELLUNAD+ is superior to NMN supplements for disease or longevity endpoints.
Age Revive chose NR because it is the NAD+ precursor with published human oral-bioavailability and multi-week tolerability data at defined doses, and because it has an established regulatory pathway as a dietary ingredient in the United States.
CELLUNAD+ pairs 500 mg of NR with methylation co-factors — TMG, 5-MTHF, methylcobalamin, and P-5-P — plus 200 mg of R-lipoic acid and 100 mg of apigenin. The co-factors are included because NAD+ metabolism draws on the body's methyl-group supply. Serving size is 2 capsules daily, 30 servings per bottle. Price: $79.99 one-time or $67.99/month with Subscribe & Save.
CELLUNAD+ is formulated to support NAD+ metabolism and cellular energy. It is a dietary supplement, not a drug. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Most NMN-versus-NR content online argues for one molecule over the other. A more useful checklist for any NAD+ precursor product:
Did Martens 2018 or Trammell 2016 test CELLUNAD+? No. Both studies evaluated nicotinamide riboside (NR) as a single ingredient in healthy adults — Trammell 2016 measured oral bioavailability after single doses, and Martens 2018 measured tolerability and blood NAD+ over six weeks at 1,000 mg per day. Neither tested the finished CELLUNAD+ formula, which provides 500 mg of NR per daily serving with methylation co-factors. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
How much NR did the Martens 2018 study use, and how does that compare to CELLUNAD+? Martens 2018 used 500 mg of NR twice daily (1,000 mg per day) for six weeks in 24 healthy adults aged 55–79. CELLUNAD+ provides 500 mg of NR per daily serving — half the study's daily dose — alongside TMG, 5-MTHF, methylcobalamin, P-5-P, R-lipoic acid, and apigenin. The study did not test CELLUNAD+. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Is NR converted to NMN in the body? Yes. Nicotinamide riboside (NR) is phosphorylated by nicotinamide riboside kinases (NRK1 and NRK2) to form nicotinamide mononucleotide (NMN), which NMNAT enzymes then convert to NAD+. Research in cells and mice (Ratajczak 2016) found NRK1 is required for cells to use either NR or NMN supplied from outside the cell, and that extracellular NMN is largely converted to NR before uptake.
Does Age Revive sell an NMN supplement? No. Age Revive does not sell NMN. Its NAD+ precursor product is CELLUNAD+, which uses 500 mg of nicotinamide riboside (NR) per daily serving. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Is nicotinamide riboside better than niacin? They take different routes to NAD+. Niacin causes flushing at higher doses, which limits how much can be used; NR does not flush and has published human pharmacokinetic data at 100–1,000 mg. "Better" for outcomes has not been tested head-to-head in humans.
Is CELLUNAD+ an NMN supplement? No. CELLUNAD+ contains nicotinamide riboside (NR), 500 mg per daily serving, as an NAD+ precursor—not NMN. Human studies of NR have evaluated NAD+ metabolism and tolerability (Martens 2018; Trammell 2016). These studies did not test the finished CELLUNAD+ formula and do not establish disease prevention or lifespan extension. The formula also includes TMG, 5-MTHF, methylcobalamin, P-5-P, 200 mg R-lipoic acid, and 100 mg apigenin. One-time price: $79.99 USD; Subscribe & Save: $67.99 USD/month. See our Science page for the cited studies. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
NMN vs NR—which does Age Revive use for cellular energy support? Age Revive's daily NAD+ foundation, CELLUNAD+, uses 500 mg of nicotinamide riboside (NR) per daily serving with co-factor support. NMN and NR are different NAD+ precursors discussed in research. The NR studies cited on our Science page (Martens 2018; Trammell 2016) do not establish that CELLUNAD+ is superior to NMN supplements for disease or longevity outcomes. We make no such superiority claim.
CELLUNAD+ product page · Science · FAQ · All Learn articles
Andy Palenzuela is the founder of Age Revive and has 14+ years of experience in regulated nutrition supply chains, including manufacturing oversight, ingredient sourcing, and quality assurance for consumer health products. Age Revive formulas are developed based on published peer-reviewed research and manufactured at cGMP-certified facilities. LinkedIn
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The information in this article is for educational purposes only and is not intended as medical advice. Consult your healthcare provider before starting any supplement regimen.